Literature DB >> 6338333

Minireview. The nephrotoxicity of cisplatin.

R S Goldstein, G H Mayor.   

Abstract

Cisplatin is a cancer chemotherapeutic agent whose clinical use is complicated by its dose related kidney toxicity. Since the histopathological profile of cisplatin nephrotoxicity appears similar to that of other heavy metals, it has been commonly presumed that cisplatin nephrotoxicity is related to the platinum moiety. However, the delayed time course and development of cisplatin nephrotoxicity is not characteristic of heavy metal nephropathy. Furthermore, cisplatin nephrotoxicity is stereospecific to the cis and not the trans isomer, indicating that the platinum atom is not the proximate nephrotoxicant. It is likely that a metabolite of cisplatin, possibly an aquated and/or hydroxylated complex, mediates the nephrotoxicity of cisplatin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6338333     DOI: 10.1016/0024-3205(83)90299-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  41 in total

Review 1.  Specific effects of reactive thiol drugs on mitochondrial bioenergetics.

Authors:  Iseli L Nantes; Tiago Rodrigues; Antonio C F Caires; Rodrigo L O R Cunha; Felipe S Pessoto; César H Yokomizo; Juliana C Araujo-Chaves; Priscila A Faria; Debora P Santana; Carolina G dos Santos
Journal:  J Bioenerg Biomembr       Date:  2011-02       Impact factor: 2.945

2.  Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis.

Authors:  Aghilès Hamroun; Rémi Lenain; Jean Joel Bigna; Elodie Speyer; Linh Bui; Paul Chamley; Nicolas Pottier; Christelle Cauffiez; Edmone Dewaeles; Xavier Dhalluin; Arnaud Scherpereel; Marc Hazzan; Mehdi Maanaoui; François Glowacki
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

3.  Pulsed focused ultrasound pretreatment improves mesenchymal stromal cell efficacy in preventing and rescuing established acute kidney injury in mice.

Authors:  Scott R Burks; Ben A Nguyen; Pamela A Tebebi; Saejeong J Kim; Michele N Bresler; Ali Ziadloo; Jonathan M Street; Peter S T Yuen; Robert A Star; Joseph A Frank
Journal:  Stem Cells       Date:  2015-04       Impact factor: 6.277

Review 4.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

5.  Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment.

Authors:  G Los; P H Mutsaers; W J Lenglet; G S Baldew; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.

Authors:  L Pendyala; S Madajewicz; S B Lele; S G Arbuck; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Potentiated nephrotoxicity of cisplatin when combined with amikacin comparing young and adult rats.

Authors:  H T Jongejan; A P Provoost; J C Molenaar
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

8.  Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide.

Authors:  H T Heidemann; J F Gerkens; E K Jackson; R A Branch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

9.  Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds.

Authors:  J Hannemann; J Duwe; K Baumann
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Effect of aminophylline on cisplatin nephrotoxicity in the rat.

Authors:  H T Heidemann; S Müller; L Mertins; G Stepan; K Hoffmann; E E Ohnhaus
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.